BRAF and melanoma: In some instances, the full potential of new agents is only realised after prolonged on-market learning of how to best use, dose, and judiciously combine them with other agents to achieve supra-additive effects; this has been shown, for example, with the combination of BRAF and MEK inhibitors which improved overall survival in melanoma BRAF mutant melanoma (Lopez and Banerji, 2017).